AVI BioPharma Announces Presentations at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual...
September 19 2011 - 8:00AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced that the Company's influenza program,
including its lead therapeutic candidate AVI-7100, will be featured
in three presentations at the 51st Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting taking
place September 17 - 20 in Chicago, IL.
Peter Sazani, Ph.D., Executive Director of Preclinical
Development at AVI, will deliver a poster presentation titled
"Toxicity and Toxicokinetic Evaluation of AVI-7100, Targeted to a
Highly Conserved Region of Influenza A Virus" at 11:15 a.m. CDT on
Monday, September 19. The presentation will be given during poster
session 180, called "New Agents Active Against Viral and
Viral-Associated Infections."
Patrick Iversen, Ph.D., Senior Vice President of Research and
Innovation at AVI, will deliver a poster presentation titled
"AVI-7100 is Effective in Oseltamivir Resistant H1N1 Infected
Ferrets" at 11:15 a.m. CDT on Monday, September 19, during poster
session 180.
Dr. Iversen will also deliver a poster presentation titled
"AVI-7100 Prevents Transmission from Oseltamivir Resistant H1N1
Viral Infected to Naïve Ferrets" at 11:15 a.m. CDT on Monday,
September 19, during poster session 180.
All presentations will be posted on the AVI BioPharma website in
the "Events & Presentations" section after their respective
sessions are completed.
About AVI-7100 AVI-7100 is AVI's lead
therapeutic candidate for the treatment of influenza, currently
being investigated in a Phase 1 clinical study. AVI-7100 targets a
well-conserved region of the influenza A virus, affording it the
potential to act as a broad-spectrum treatment for multiple
influenza strains, including Tamiflu-resistant flu strains.
Seasonal influenza (H3N2) and the more recently emergent swine
origin influenza virus (SOIV), H1N1, are both caused by the
influenza A virus. AVI-7100 employs the Company's patented PMOplus™
technology that selectively introduces positive charges to a
phosphorodiamidate morpholino oligomer (PMO) backbone to improve
selective interaction between the drug and its target. AVI-7100 was
preclinically developed and identified as the lead candidate with
support from the U.S. Department of Defense's Joint Project Manager
Transformational Medical Technologies (JPM-TMT) under contract
HDTRA1-09-C-0046.
Preclinical studies funded under JPM-TMT contract
HDTRA1-10-C-0079 demonstrated that AVI-7100 improved clinical
symptoms and reduced viral titers in animal models infected with
pandemic H1N1 or H3N2 viruses, and had statistically significant
activity as compared to saline and Tamiflu controls.
About AVI BioPharma AVI BioPharma is
focused on the discovery and development of novel RNA-based
therapeutics for rare and infectious diseases, as well as other
select disease targets. Applying pioneering technologies developed
and optimized by AVI, the Company is able to target a broad range
of diseases and disorders through distinct RNA-based mechanisms of
action. Unlike other RNA-based approaches, AVI's technologies can
be used to directly target both messenger RNA (mRNA) and precursor
messenger RNA (pre-mRNA) to either down-regulate (inhibit) or
up-regulate (promote) the expression of targeted genes or proteins.
By leveraging its highly differentiated RNA-based technology
platform, AVI has built a pipeline of potentially transformative
therapeutic agents, including eteplirsen, which is in clinical
development for the treatment of Duchenne muscular dystrophy, and
multiple drug candidates that are in clinical development for the
treatment of infectious diseases. For more information, visit
www.avibio.com.
Forward-Looking Statements and Information
In order to provide AVI's investors with an understanding of its
current results and future prospects, this press release contains
statements that are forward-looking. Any statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "will," "intends,"
"potential," "possible" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements include statements about the development of AVI's
product candidates, their efficacy, potency and utility in the
treatment of rare and infectious diseases and their potential to
treat a broad number of human diseases.
These forward-looking statements involve risks and
uncertainties, many of which are beyond AVI's control. Known risk
factors include, among others: clinical trials may not demonstrate
safety and efficacy of any of AVI's drug candidates and/or AVI's
antisense-based technology platform; and any of AVI's drug
candidates may fail in development, may not receive required
regulatory approvals, or be delayed to a point where they do not
become commercially viable.
Any of the foregoing risks could materially and adversely affect
AVI's business, results of operations and the trading price of
AVI's common stock. For a detailed description of risks and
uncertainties AVI faces, you are encouraged to review the official
corporate documents filed with the Securities and Exchange
Commission. AVI does not undertake any obligation to publicly
update its forward-looking statements based on events or
circumstances after the date hereof.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
AVI Media and Investor Contact: Erin Cox Manager, Corporate
Communications and Investor Relations 425.354.5140 Email Contact
AVI Media Contact: David Schull Russo Partners 858.717.2310 or
212.845.4271 Email Contact
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024